Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S418000, C548S484000, C548S491000, C548S504000
Reexamination Certificate
active
07084167
ABSTRACT:
The invention concerns compounds of general formula (I) wherein: the group X represents a —NR4, —CH═N or —CHR5-NR4-group; the group Y represents an oxygen or sulphur atom or a NR, —CR5, —CHR5-, —CR5=CR6- or —CHR5-CHR6 group provided that when group X represents the —CH═N— or —CHR5-NR4-group, group Y represents an oxygen or a sulphur atom or a Nr, —CR5 or —CHR group; the group R represents a hydrogen atom or an alkyl, aryl or aralkyl group; the groups R1, R5 and R6, identical or different, represent each a hydrogen or halogen atom or an alkyl or alkoxy group; the group R2 represents a hydrogen atom or an alkyl group; the group R3 represents an aryl group; and the group R4 represents a hydrogen atom, an alkyl, aryl, aralkyl, alkylsulphonamide, arylsulphonamide or aralkylsulphonamide group; and their salt with a pharmaceutically acceptable acid, in the form of a racemic mixture and their optically pure isomer. The invention also concerns their preparation, pharmaceutical compositions containing them and their use as CaSR activity modulator and as medicine for preferably treating diseases or physiological disorders involving the intervention of CaSR activity modulation.
REFERENCES:
patent: 3906099 (1975-09-01), Morrison et al.
patent: 542696 (1985-04-01), None
patent: 2010406 (1989-01-01), None
patent: WO 93/04373 (1993-03-01), None
patent: WO 96/12697 (1996-05-01), None
patent: WO 96/23789 (1996-08-01), None
patent: WO 00/21910 (2000-04-01), None
patent: WO 00/32578 (2000-06-01), None
patent: WO 00/35864 (2000-06-01), None
patent: WO 01/34562 (2002-05-01), None
Cruces, et al., “Acetylenic and Allenic Derivatives of 2-(1-methylindolyl)methylamine As Selective Inhibitors of the Monoamine Oxidases A and B,” Farmaco, Edizione Scientifica, vol. 43, Iss. 7-8, p. 567-73 (1988).
Cherqaoui et al.; Structure-selectivity relationship of MAO inhibitors using neural networks; Models in Chemistry 135 (1-2), pp. 79-91 (1998).
Ferry et al.; Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary cells, Biochem. and Biophys. Res. Comm. 238, pp. 866-873 (1997).
Nemeth et al.; Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism, TEM, vol. 10, No. 9, pp. 66-71 (1999).
Ye et al.; Amyloid-62 proteins activate CA2+permeable channels through calcium-sensing receptors, J. Neuroscience Res. 47:547-554 (1997).
Antonsen et al.; A cacimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure; Kidney International, 53:223-227 (1998).
Wada et al.; NPS R-568 halts or reverses osteitis fibrosa I uremic rats; Kidney International 53:448-453 (1998).
Wada et al.; The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency; INIST CNRS 2977-2983 (2002).
Silverberg et al.; Short-term inhibition of parathyroid hormone secretion by a calcium receptor agonist in patients with primary hyperparathyroidism, New England Journal of Medicine, 1506-1510 (1997).
Brown et al.; The extracellular calcium-sensing receptor: Its role in health and disease; Annu. Rev. Med. 49:15-29 (1998).
Brown et al.; Cloning and characterization of an extracellular CA2+ sensing receptor from bovine parathyroid; Nature 366:575-580 (1993).
Nemeth et al.; Calcimimetics with potent and selective activity on the parathyroid calcium receptor, PNAS 95:4040-4045 (1998).
Pollak et al.; Autosomal dominant hypocalcaemia caused by a CA2+ sensing receptor gene mutation, Nature Genetics, 8:303-307 (1994).
Ruat et al.; Calcium sensing receptor: Molecular cloning in rat and localization to nerve terminals; PNAS 92:3161-3165 (1995).
Ruat et al.;Cloned and expressed rat CA2+ sensing receptor; J. Biol. Chem., 271:5972-5975 (1996).
Pollak et al.; Mutations in the human CA2+ sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism, Cell, 75:1297-1303 (1993).
Chattopadhyay et al.; The calcium-sension receptor: A window into the physiology and pathophysiology of mineral ion metabolism; Endocrine 17(4):289-307 (1996).
Gavela et al.; Preparacion de derivados acetilenicos y alenicos de 2-indolilmetilaminas y resultdos preliminaries de su estudio como inhibidores selectivos para las monoaminooxidasaas AYB; 82:129-120 (1986).
Nogradi, Thomas; Untersuchungen uber rauwolfia-alkaloid-modelle II; 2-substituierte indole, tetrahydrocarbolin und hexadehydro-yohimban-derivate; Monatshefte fur Chemie. Bd. 88(6) 1088-1094 (1957).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161450 (1987).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161408 (1996).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161449 (1986).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161453 (1996).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161448 (1998).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161454 (1998).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161455 (1986).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161456 (1985).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161451 (1958).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161457 (1958).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161464 (1989).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161465 (1989).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161452 (1978).
6001 Chemical Abstracts, Columbus, Ohio; XP-002161458 (1978).
Dauban Philippe Marcel
Dodd Robert
Faure Hélène Véronique
Kessler Albane
Potier Pierre Jean-Paul
Centre National de la Rechereche Scientifique (CNRS)
Foley & Lardner LLP
Freistein Andrew B.
Saeed Kamal A.
LandOfFree
Calcium receptor active molecules and method for preparing same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium receptor active molecules and method for preparing same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium receptor active molecules and method for preparing same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3667225